FMG Internship Extension from 2 to 3 years in MP: High Court Defers hearing to June 23

Bhopal: The plea challenging the extension of the Foreign Medical Graduate (FMG) internship period has been deferred by the Madhya Pradesh High Court.

Altogether, nine medical graduates from abroad had challenged the extension of their mandatory internship period from 2 years to 3 years by the State. Even though the matter was listed for hearing on June 19, 2025, it has now been scheduled for further hearing on June 23, 2025.

According to the existing rules, foreign medical graduates must undergo one year of internship in a medical college of the State after completing their medical education abroad. This is necessary to be able to get a permanent registration to practice medicine in India. During the COVID-19 outbreak, the duration of the internship was increased to two years.

Medical Dialogues had earlier reported that a group of FMGs had filed a plea before the Madhya Pradesh High Court when their internship tenure was extended from 2 to 3 years just before they were going to complete their internship. They claimed that the MP Medical Council increased the duration of their internship by another year when only four months were left to complete the internship. While they were about to complete the internship term in March 2025, they were informed on November 4, 2024, that their internship period would now be for a period of three years.

Also Read: FMG Internship Extension from 2 to 3 years in MP: HC notice to state, NMC, Medical Council

Previously, while considering the plea, the Madhya Pradesh High Court had sought to know the stand of the State Government and the State Medical Council regarding the matter. During the hearing of the case on May 19, a Division bench of the High Court comprising Justices Sanjeev Sachdeva and Vinay Saraf sought clarification from the National Medical Commission (NMC) regarding the reason behind 2 years of clerkship for the FMGs to compensate for their online training.

The petitioners’ counsel had argued before the Court that the NMC circular had been incorrectly been applied to the petitioners and other students who had pursued the medical course in China as the circular was applicable only to those who studied in Ukraine and later it had been clarified to apply the same for the students in Phillippines as well. However, it had no application for the students in China.

Recently, in the order dated May 2, considering the fact that the last date to apply for the NEET PG 2025 examination is 7th May 2025, the Court had allowed them to fill out the NEET PG exam form.

Later, granting interim relief to these medical graduates from abroad, the Madhya Pradesh High Court provisionally allowed them to appear in the National Eligibility-Entrance Test for Postgraduate (NEET-PG) 2025 examination.

Also Read: ‘What’s the Logic Behind 2-Year Clerkship?’: MP HC asks NMC, Allows 9 FMGs to Appear for NEET PG 2025

Powered by WPeMatico

Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag International

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for an indication extension of IMBRUVICA (ibrutinib) in frontline mantle cell lymphoma (MCL).

Ibrutinib is a once-daily oral medication that is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. Ibrutinib blocks the BTK protein, which is needed by normal and abnormal B-cells, including specific cancer cells, to multiply and spread. By blocking BTK, ibrutinib may help move abnormal B-cells out of their nourishing environments and inhibits their proliferation.

The recommendation is for ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (ibrutinib + R-CHOP) alternating with R-DHAP (or R-DHAOx)* without ibrutinib, followed by ibrutinib monotherapy, for the treatment of adult patients with previously untreated MCL who would be eligible for autologous stem cell transplant (ASCT). The extended indication is based on data from the pivotal Phase 3 TRIANGLE study.

“The CHMP recommendation is an important milestone for patients with previously untreated MCL, an aggressive disease which requires complex and challenging treatment,” said Ester in’t Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. “We are excited by the innovation that ibrutinib continues to bring and hope to soon offer patients this frontline option that has demonstrated improved overall survival without the burden, toxicity and time in hospital associated to an ASCT-based treatment regimen.”

The CHMP recommendation for ibrutinib is supported by data from the randomised Phase 3 TRIANGLE study, conducted by the European MCL Network ( NCT02858258 ), which evaluated 870 patients across three treatment arms to assess whether the addition of ibrutinib to chemotherapy with or without ASCT could improve outcomes and potentially remove the need for transplant in patients with previously untreated MCL who were suitable for high-dose treatment. The study demonstrated that adding ibrutinib to chemotherapy followed by a 2-year fixed-duration maintenance period instead of ASCT provides significantly longer overall survival and superior failure-free survival compared to the chemotherapy regimen including ASCT.

“At Johnson & Johnson, we are committed to improving outcomes for patients facing complex blood cancers,” said Jessica Vermeulen, Vice President, Lymphoma & Leukemia Disease Area Stronghold Leader, Johnson & Johnson Innovative Medicine. “The TRIANGLE study, conducted by the European MCL Network, affirms the potential emergence of a new standard of care for transplant eligible patients diagnosed with MCL and represents the first major step forward for these patients in many years. We look forward to working together to bring this transplant-free therapeutic option to the MCL community.”

MCL is a rare, aggressive form of non-Hodgkin lymphoma. The current standard of care in the frontline setting for young and fit patients is a chemotherapy regimen including ASCT, which can be associated with severe toxicities, lengthy hospital stays and high health resource utilisation. The addition of fixed-duration ibrutinib to chemotherapy offers the potential for long treatment-free remissions while avoiding the burden of stem cell transplant. If approved, ibrutinib would become the first Bruton’s Tyrosine Kinase inhibitor (BKTi) for frontline treatment of transplant eligible MCL patients.

Ibrutinib is approved in more than 100 countries and has been used to treat more than 325,000 patients worldwide. There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of ibrutinib. In October 2021, ibrutinib was added to the World Health Organization’s Model Lists of Essential Medicines (EML), which refers to medicines that address global health priorities and which should be available and affordable for all.

Ibrutinib was first approved by the European Commission (EC) in 2014, and approved indications to date include:

  • As a single agent or in combination with rituximab or obinutuzumab or venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
  • As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy
  • As a single agent for the treatment of adult patients with relapsed or refractory MCL
  • As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. In combination with rituximab for the treatment of adult patients with WM

Powered by WPeMatico

AIIMS INI CET July 2025 Round 1 results on June 25- Check out seat allocation Guidelines

New Delhi- The All India Institute of Medical Sciences (AIIMS) New Delhi recently released the provisional information brochure for the 1st and 2nd round of online seat allocation (Institute and subject/Speciality)/ process for [MD/MS/DM(6yrs.)/MCH(6yrs.)/MDS] for the July 2025 session.

Through the brochure, the AIIMS New Delhi has detailed the important information for the candidates, such as eligibility, procedure, age limit, etc. The brochure has been released on the official website of AIIMS New Delhi.

Below are the complete details-

Also Read: AIIMS INI CET July 2025 Counselling Schedule Out, 1360 seats available for candidates, Check out FAQs

ELIGIBILITY

All the candidates who have been listed in the Result will be eligible to participate in the 1st and 2nd Round of the Online Seat Allocation, except rank of OBC/EWS candidates lower than the cut-off rank of UR who failed to produce a valid category certificate.

PROCEDURE

1 The eligible candidates will have to Login themselves to the PG Online Seat Allocation portal. The link for the portal will be activated only for eligible candidates in the MyPage and password may be reset by click on “Forgot Password” button and also an email containing link for the online seat allocation Portal and login credentials (Login ID and Password) will be sent to the registered email address of the eligible candidates. To retrieve the login credentials, click on the Forgot your login details button on the Registration/login Page.

2 The PG Online Seat Allocation portal will allow candidates to make choices of seats (a combination of Institute and subject/speciality) as per his/her eligibility. The candidate can arrange the choices in the desired order of preference. There is no limitation on the number of choices (Institute & Subject/Speciality) that can be made by the candidates. The choices can be edited and reordered within the date and time specified in the Important Dates link in the Portal.

3 Kindly note that the choices cannot be edited and reordered after the closing date of exercising of Choice of the 1st Round of seat allocation. The allocation of the 2nd Round will be done as per the choices made by the candidates during the exercise of the Choice of the 1st Round of seat allocation.

4 The Portal will remain open on dates specified in the Important Dates link in the Portal. The choices made by the candidate will be locked either by the candidate OR will be automatically locked on the last Date and Time as specified in the Important Dates link in the Portal.

5 A Mock Seat Allocation will be done prior to the 1st Round of Seat Allocation (not a final allocation). The mock seat allocation represents the likely seat that a candidate may be allocated as per choices made by the candidate. The result of the mock round seat allocation will be announced as per the date specified in the Important Dates link. The candidate can register/edit/reorder their choices before the closing dates of choices for the 1st Round as per the Important Dates link in the Portal.

6 Those who will not login during exercising of choices (Institute and subject/speciality) for First Round their order of choice will be considered as per choices made during Mock Round.

UPPER AGE LIMIT

1 NIMHANS, Bengaluru (As on 1st July 2025): The age validation for Courses of NIMHANS under INI-CET for July 2025 session

For MD Psychiatry Course-

1 General/Unreserved Category’- 32 Years (Candidates Born on or after 01.07.1993 are eligible).

2 ‘OBC Category’- 35 Years (Candidates Born on or after 01.07.1990 are eligible).

3 ‘SC/ST/PWBD Category’-37 Years (Candidates Born on or after 01.07.1988 are eligible).

4 ‘Sponsored Category’- 45 Years (Candidates Born on or after 01.07.1980 are eligible).

DM (Neurology), M.Ch. Neurosurgery (Post MBBS category) Course & MD Physical Medicine & Rehabilitation- 32 Years (Candidates Born on or after 01.07.1993 are eligible).

2 SCTIMST Trivandrum (As on 1 st July 2025): The age validation for Courses of SCTIMST under INI-CET for July 2025 session-

i General/Unreserved/ EWS/Foreign National category- 40 Years (candidates Born on or after 01.07.1985 are eligible).

ii SC/ST/ Ex-service personnel/PwBD – 45 Years (Candidates Born on or after 01.07.1980 are eligible).

iii OBC – 43 Years (Candidates Born on or after 01.07.1982 are eligible).

iv Sponsored– 50 Years (Candidates Born on or after 01.07.1975 are eligible).

INSTITUTE PREFERENCE

1 AIIMS New Delhi & other AIIMS- The allocation of Institute preferences will be done as per Roster Point Allocation for Counselling (Dynamic) which will be announced separately.

2 JIPMER, Puducherry: Allocation of Institute preference for JIPMER Puducherry candidates, seats shall be done as per Roster Point (Dynamic).

3 NIMHANS, Bengaluru: No seat available for Institute Preference.

4 PGIMER, Chandigarh: No seat available for Institute Preference.

5 SCTIMST, Trivandrum: No seat available for Institute Preference.

FOREIGN NATIONAL CANDIDATES

The seat allocation will be done in order of merit and according to choices made by the candidates.

1 The candidates will be eligible to exercise of choice only as per Subject/ Institute those are filled in the online registration form.

2 All allocation of Foreign National candidates will be done on the basis of as per Subject/Institute filled in the online registration for July 2025 session.

3 Only one best Subject/Speciality and Institute available at that rank will be allocated during online seat allocation.

4 The process of admission will be done as per procedure available for other candidates.

SPONSORED CANDIDATES

1 The seat allocation will be done in order of merit and according to choices made by the candidates.

2 In case any discrepancy found in online data with Sponsorship certificate valid information as in Sponsorship certificate will be accepted as per eligibility criteria.

3 The candidates are eligible to exercise of choice only as per Subject/ Institute those are available in the Sponsorship Certificate.

4 In case, the NOC has been received in place of Sponsorship certificate, the seat allocation will be done as per subject/Institute available in the online registration.

5 If the subject is not mentioned against the candidate name in the Sponsorship certificate, no allocation will be done for that institute.

6 If the subject is not mentioned against the candidate name in the Sponsorship certificate, but subject is available in the online registration, the candidate can make exercising of choices as per subject available in the online registration.

7 All allocation of Sponsored candidates will be done on the basis of Subject/Institute available in the Sponsorship Certificate/online registration for July 2025 session.

8 Only one best Subject/Speciality and Institute available at that rank will be allocated during online seat allocation.

9 The process of admission will be done as per procedure available for other candidates.

ONLINE PG SEAT ALLOCATION PROCESS

Only the eligible candidates will be able to exercise their choices (Institute and subject/speciality) for online PG Seat allocation except rank of OBC/EWS candidates lower than the cut off rank of UR who failed to produce valid category certificate.

The eligible candidates will have to Login themselves on PG Online Seat Allocation portal. The link for the portal will be activated only for eligible candidates in the MyPage and password may be reset by click on “Forgot Password” button and also an email containing link for the online seat allocation Portal and login credentials (Login ID and Password) will be sent to the registered email address of the eligible candidates.

To retrieve the login credentials, click on the Forgot your login details button in the Registration/login Page.

REGISTRATION FOR THE ONLINE PG SEAT ALLOCATION PROCESS

An email containing link for the online seat allocation Portal and login credentials (Login ID and Password) will be sent to the registered email address of the eligible candidates. Further candidate can also login through their MyPage on clicking the link for online seat allocation, the eligible candidates will be directed to online PG Seat allocation portal where the candidates will have to login by click on “Forgot Password” button for online seat allocation. This password is only to access the online PG Seat allocation portal.

The candidate will be able to login to the online PG Seat allocation portal and begin the process of making choices (Institute and subject/speciality) and order the choices. The online PG Seat allocation portal will be remained open for date and time specified in the Important Dates link.

MAKING CHOICES

The choices can only be made after you have registered and logged in using the new password for this portal. On logging in, confirm your name and candidate ID. Click on Make Choice button to proceed to exercise choices (Institute and subject/speciality) and their order. To add a choice, choose the Institute and the subject/speciality from the two separate drop-down menus and Click Add choice. To remove a choice, click on Delete button against that Choice (Institute and subject/speciality). Click on the Save button to save the choices of Institute and subject/speciality and their order.

The default order of your choices (Institute and subject/speciality) will be the order in which you add choice (Institute and subject/speciality). To reorder your choices, use up and down arrows OR Drag and Drop the choice (Institute and subject/speciality) to appropriate position in the list.

Candidates can make choices (Institute and subject/speciality), edit or reorder them as many times they wish UNLESS they have already submitted and locked the choices (Institute and subject/speciality) OR last date and time 1 st Round is over. The candidate must save the choices (Institute and subject/speciality) in case they wish to add/delete/reorder them at a later time point (before the last date and time for 1 st Round).

SUBMITTING AND LOCKING CHOICES

The candidate should click on the Submit and Lock Choices tab and tick the check box ‘I accept the declaration’ and click on the submit and Lock choices (Institute and subject/speciality). Note that it will be prompted twice to reconsider and after it have been submitted and locked the choices (Institute and subject/speciality), it cannot change it for further Rounds.

In case the candidate has made and saved choices but could not submit and Lock choices, the last saved choices (Institute and subject/speciality) and their order will be automatically considered as submitted and locked choices (Institute and subject/speciality).

VIEWING AND PRINTING THE CHOICES AFTER SUBMISSION

The candidate can view the choices submitted and locked by them by clicking on the View choices button after logging in the online PG Seat allocation portal. Click Print button to take a printout. In case of any discrepancy please send a query to the Assistant Controller (Examinations) Through the help/query section of choice making dashboard.

Medical Dialogues has recently reported regarding the schedule of Online Seat Allocation for admission to Postgraduate (PG) courses of INIs [MD/MS/DM(6yrs.)/MCH(6yrs.)/MDS] INI-CET for the July 2025 session.

Below is the complete schedule-

SCHEDULE FOR 1ST ROUND OF ONLINE SEAT ALLOCATION (INCLUDING MOCK ROUND)

S.NO

PARTICULARS

DATE, DAY & TIME

1

Exercising of Choices (Institute and subject/speciality) for Mock Round.

14 June 2025 (Saturday) to 17 June 2025 up to 05.00 pm (Tuesday)

2

Announcement of Seat Allocation of Mock of 1st Round.

18 June 2025 (Wednesday)

3

Exercising of Choices (Institute and subject/speciality) for First Round.

18 June 2025 (Wednesday) to 20 June 2025 up to 05:00 PM (Friday)

4

Announcement of seat allocation of 1st Round.

25 June 2025 (Wednesday)

5

Online Acceptance of the allocated seat.

26 June 2025, 11.00 am (Thursday) to 30 June 2025 up to 05.00 pm (Monday)

6

Reporting & Submission of Documents/Security Deposit.

26 June 2025, 11.00 am (Thursday) to 30 June 2025, up to 05.00 pm (Monday)

SCHEDULE FOR 2ND ROUND OF ONLINE SEAT ALLOCATION

S.NO

PARTICULARS

DATE, DAY & TIME

1

Announcement of Seat Allocation of 2nd Round.

10 July 2025 (Thursday)

2

Online Acceptance of the allocated seat.

11 July 2025, 11.00 am (Friday) to 16 July 2025, up to 05.00 pm (Wednesday)

3

Reporting & Submission of Documents/Security Deposit.

11 July 2025, 11.00 am (Friday) to 16 July 202,5 up to 05.00 pm (Wednesday)

To view the brochure, click the link below

https://medicaldialogues.in/pdf_upload/aiims-ini-cet-july-2025-counselling-know-complete-eligibility-procedure-key-guidelines-for-1st-2nd-round-pg-seat-allocation-290966.pdf

Powered by WPeMatico

AIIMS PATNA JOBS 2025: Apply For JR Post Vacancies, Check Last Date Here

Patna: The All India Institute of Medical Sciences, (AIIMS Patna) has invited online applications for the post of Junior Resident (Non- Academic) on an Ad hoc basis.

AIIMS, Patna an Autonomous Institute of National Importance is one of the new AIIMS and apex healthcare Institutes established by the Ministry of Health & Family Welfare, Government of India under the Pradhan Mantri Swasthya Suraksha Yojna (PMSSY).

AIIMS Patna Vacancy Details:

Total No of Vacancies: 43

The last date for online submission of application is 9th JULY 2025.

For more details about Qualification, Age, Pay Allowance, and much more, click on the given link below:
https://medicaljob.in/job/junior-resident-non-academic-all-india-institute-of-medical-sciences-india-bihar-2-17-06-2025

Eligible Candidates (How to Apply):-

APPLICATION PROCESS:

Candidates, who are fulfilling the eligibility criteria may fill the application form which will be available at www.aiimspatna.edu.in. After final submission of form, candidates have to take a print of the same, which along with following documents (original and one set of self-attested copies) needs to be produced at the time of interview:-

a. Date of Birth/SSC/HSSC pass certificate (mentioning Date of Birth)

b. MBBS Degree Certificate

c. Internship Completion Certificate

e. UG/PG NMC/State Registration Certificate

f. Category/PwBD Certificate (If seat is claimed in reserved category)

g. Experience Certificate, if any

NOC from present employer (applicable for those working in Govt./Pvt. organization)

h. Any other relevant documents (viz. Research Work, Publication etc.)

For filling up of online application, candidates must have the following pre-requisites ready:

1. Valid E-mail ID and Mobile Number.

2. Scanned recent Passport size photograph of candidate (in JPG format).

3. Scanned signature of the candidate (in JPG format).

4. Online payment detail of the required application fee.

5. Aadhar Card.

b) Guidelines for scanning/uploading the Photograph, Signature, Date of Birth/SSC/HSSC Pass certificate (mentioning Date of Birth), MBBS Medical Council Registration, MBBS Degree Certificate, Category/PwBD Certificate (if seat is claimed in reserved category), Experience Certificate, NOC (if applicable) & Any other relevant documents ( if any) viz. Research Work, Publication etc.): Before applying online application form, a candidate will be required to have a scanned (digital) image of the above mentioned certificates/documents as per the specifications

Also Read:200 JR Post Vacancies 2025: Walk In Interview At AIIMS Kalyani, Hurry To Check Details

Powered by WPeMatico

Emcure Pharma to acquire remaining stake in arm Zuventus Healthcare

Pune: Emcure Pharmaceuticals has announced that its
Board of Directors has approved to enter into agreement with minority shareholders of Zuventus
Healthcare Ltd., one of its subsidiaries, to acquire their shareholding.

Following the completion of this
transaction, Zuventus will become a wholly owned subsidiary of Emcure.

The transaction is expected
to close in Q2 FY 2026.

“The domestic market remains a strategic priority for Emcure. This transaction will enable full financial
consolidation of Zuventus and drive long-term value creation for Emcure, through alignment across its
domestic business and unlock synergies,” Emcure stated in a release.

In April, Tillomed Laboratories Limited, a subsidiary of Emcure Pharma and a European pharma company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited (collectively Manx).

Read also: Emcure Pharma European arm Tillomed buys strategic pharma portfolio from Manx for 19.7 million pounds

Also in April, Gennova Biopharmaceuticals Ltd., another Emcure subsidiary, announced the advancement of the development of a pathbreaking self-amplifying mRNA (saRNA) vaccine against the deadly Nipah virus. Nipah virus belongs to the Paramyxovirus family. It is one of the deadliest pathogens known to infect humans. So far, Nipah outbreaks have been confined to South and Southeast Asia, but the fruit-bat vector is found in large geographical areas across the globe covering a population of more than 2 billion people.

Read also: Emcure Pharma arm Gennova advances development of Nipah virus vaccine

Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune
engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical
products. Emcure is an R&D
driven company that develops and manufactures a wide range of differentiated pharmaceutical
products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.

Read also: Emcure Pharma Anil Kothiyal to resign as President – India Sales & Marketing

Powered by WPeMatico

Mismatch repair germline pathogenic variants could predispose to uveal melanoma

Mismatch repair (MMR) germline alterations are enriched among patients with uveal melanoma (UM), according to a study published online June 18 in JAMA Ophthalmology.

Powered by WPeMatico

Racial, ethnic differences seen in teens’ use of mental health services

There are substantial racial and ethnic differences in U.S. adolescents’ use of mental health services, according to a study published online June 18 in JAMA Network Open.

Powered by WPeMatico

Computational tool exposes hidden cancer DNA changes that may drive treatment resistance

Some of the most harmful genetic changes in cancer are also the hardest to see. These structural alterations, deep within a tumor’s DNA, can fuel aggressive growth and evade standard testing, especially when tissue samples are small or degraded.

Powered by WPeMatico

Genetics of cardiomyopathy risk in childhood cancer survivors differ by age of onset, study shows

The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from St. Jude Children’s Research Hospital have helped address this gap, assessing whether variant trends seen in the general population also apply to late-onset cardiomyopathy in five-year survivors of childhood cancer.

Powered by WPeMatico

Up to 40 years to get diagnosed with lupus: Research highlights devastating impact of delays on patients

New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that can last decades—in diagnosing lupus, an auto-immune condition.

Powered by WPeMatico